Terrence Bradley
Overview
Explore the profile of Terrence Bradley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel A, Yoon J, Johnston H, Davidson M, Shallis R, Chen E, et al.
Blood Adv
. 2024 May;
8(13):3468-3477.
PMID: 38739724
Progression of myeloproliferative neoplasms (MPNs) to accelerated or blast phase is associated with poor survival outcomes. Since 2017 there have been several therapies approved for use in acute myeloid leukemia...
2.
Itonaga H, Mookhtiar A, Greenblatt S, Liu F, Martinez C, Bilbao D, et al.
Nat Commun
. 2024 Apr;
15(1):3415.
PMID: 38649367
An important epigenetic component of tyrosine kinase signaling is the phosphorylation of histones, and epigenetic readers, writers, and erasers. Phosphorylation of protein arginine methyltransferases (PRMTs), have been shown to enhance...
3.
Bradley T, Kwon D, Monge J, Sekeres M, Chandhok N, Thomassen A, et al.
EJHaem
. 2022 Dec;
3(4):1231-1240.
PMID: 36467830
Hispanic patients have been reported to have an increased incidence of AML and possibly inferior outcomes compared to non-Hispanics. We conducted a retrospective study of 225 AML patients (58 Hispanic...
4.
Nguyen N, Madarang E, Alencar A, Watts J, Bradley T
Leuk Res Rep
. 2022 Nov;
18:100355.
PMID: 36338830
Jehovah's Witnesses cannot accept blood products based upon religious beliefs, and when they present with acute leukemia, the ideal treatment strategy can be controversial. We present six cases of Jehovah's...
5.
Nguyen N, Chaudhry S, Totiger T, Diaz R, Roberts E, Montoya S, et al.
NPJ Precis Oncol
. 2022 Oct;
6(1):73.
PMID: 36261486
Patients with multiple myeloma-bearing translocation t(11;14) have recently been shown to benefit from the apoptosis-inducing drug venetoclax; however, the drug lacks FDA approval in multiple myeloma thus far due to...
6.
Daver N, Perl A, Maly J, Levis M, Ritchie E, Litzow M, et al.
J Clin Oncol
. 2022 Jul;
40(35):4048-4059.
PMID: 35849791
Purpose: The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory -mutated () acute myeloid leukemia (AML) but seldom reduces burden or induces sustained efficacy. Gilteritinib combines...
7.
Singh A, Thota S, Bradley T, Griffiths E, Faber M, Sadek S, et al.
Clin Lymphoma Myeloma Leuk
. 2021 May;
21(9):613-620.
PMID: 34031004
Background: The optimal approach to combine gemtuzumab-ozogamicin (GO) with various chemotherapy backbones and other newer agents safely remains to be determined. Materials And Methods: We performed a retrospective analysis of...
8.
Raja M, Natori Y, Chandorkar A, Camargo J, Simkins J, Andrews D, et al.
Open Forum Infect Dis
. 2020 Sep;
7(9):ofaa372.
PMID: 32995351
Severe acute respiratory syndrome coronavirus 2 is associated with severe disease in patients with hematologic malignancy. We report a series of patients with underlying hematologic malignancy and coronavirus disease of...
9.
Bradley T, Zuquello R, Aguirre L, Mackrides N, Chapman J, Cimmino L, et al.
Leuk Res Rep
. 2020 Jun;
13:100204.
PMID: 32477862
Acute myeloid leukemia (AML) is defined by the presence of ≥ 20% myeloblasts in the blood or bone marrow. Spontaneous remission (SR) of AML is a rare event, with few...
10.
Watts J, Bradley T
Clin Cancer Res
. 2020 Apr;
26(13):3073-3076.
PMID: 32284317
Cytarabine is the backbone of AML therapy, but the dose used during induction has remained controversial. Using an intermediate dose of cytarabine, compared with conventional dose, was shown to improve...